Bright Path draws on its groundbreaking advanced technology and passionate team of world-class scientists to perform rapid drug development. We simultaneously offer formulation services and manufacturing abilities to provide clients with smooth project integration. Our agile approach offers accelerated proof-of-concept to manufacturing scale and fast go/no go decisions. By introducing scalable flow chemistries during early candidate development, we take advantage of the benefits of a continuous process throughout the material value chain. Continuous flow methods also allow Bright Path scientists to perform difficult chemistries safely, enabling our team to quickly assess drug viability and future steps. Leverage a sustainable, efficient, and innovative process: work with Bright Path to explore and perform drug development.
Bright Path Labs is proud to announce its admittance to the Green Chemistry and Commerce Council (GC3)! We are eager to learn from and collaborate with leaders in sustainable and green technologies across different sectors. Our technology and approach are deeply rooted in Green Chemistry’s 12 Principles, so we are thrilled to participate in an organization of firms that uphold and put into practice these fundamentals. Read more about Bright Path’s recent ascension into the group at Startup Cohorts...
Supply chain disruption will be with biopharmaceutical companies for the foreseeable future, according to the recent CFO survey, Supply Chain Resilience, by BDO. A separate report by Catalent, Allogeneic and Autologous Cell Therapies Report 2022, agrees, saying, “Bottlenecks are one of the most common hurdles facing cell and gene therapy developers.”
Drilling down to identify specific concerns, BDO found that global life science companies are most concerned about rising materials cost (51%), supplier...
Bright Path Labs has appointed Mr. Marc Fasteau as an independent director. Tony Quinones, CEO of BPL, stated, “We are extraordinarily honored and pleased that Mr. Fasteau has elected to join our board as an independent director.” Mr. Fasteau is a lawyer, former partner at New York investment bank Dillon Read and founder and former chairman of the American Strategic Insurance, property & casualty insurance group. Mr. Fasteau serves on the board of Oxford Performance Materials, a privately held...
Sparta Systems, provider of Quality Management System (QMS) platforms TrackWise and TrackWise Digital, has announced that Bright Path Laboratories, a leader in continuous-flow reactor technology, has selected TrackWise Digital as their QMS of the future.
Bright Path Labs will implement TrackWise Digital’s platform for end-to-end quality management, document management, and training management.
Bright Path Labs will also leverage the strategic partnership between Sparta and Quartic, and the combined...
Bright Path Laboratories, Inc. (privately held) 3-year-old startup contract manufacturer – with offices in both Charlotte and Santa Fe, N.M. – recently got a strong show of support from The U.S. Food and Drug Administration for its patented spinning-tube-in-tube (STT) continuous-flow reactor.
The agency accepted the system, the only one of its kind that manufactures active pharmaceutical ingredients (APIs), into the FDA’s Emerging Technology Program. That program promotes innovative approaches...
Customer reviews
No reviews were found for Bright Path - Rapid Drug Development Service. Be the first to review!
